Treating Non-Small-Cell Lung Cancer First Line with Erlotinib Monotherapy in Elderly Patients: Discussion of a Case Series

Publisher： Karger

E-ISSN： 2296-5262|30|10|515-518

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.30, Iss.10, 2007-09, pp. : 515-518

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Erlotinib for Metastatic Non-Small-Cell Lung Cancer: First-, Second- or Third-Line Setting – Does It Matter ?

By  

Oncology, Vol. 76, Iss. 2, 2008-12 ,pp. : 85-90

Karger

Access to resources Recommend Favorite

Benefit of Erlotinib in Patients with Non-Small-Cell Lung Cancer Is Related to Smoking Status, Gender, Skin Rash and Radiological Response but Not to Histology and Treatment Line

By  

Oncology, Vol. 78, Iss. 3-4, 2010-06 ,pp. : 249-258

Karger

Access to resources Recommend Favorite

Erlotinib in Patients with Previously Irradiated, Recurrent Brain Metastases from Non-Small Cell Lung Cancer: Two Case Reports

By  

Oncology Research and Treatment, Vol. 31, Iss. 3, 2008-02 ,pp. : 123-126

Karger

Access to resources Recommend Favorite

Evaluation of the Efficacy and Safety of the Combination of Gemcitabine and Nedaplatin for Elderly Patients with Advanced Non-Small-Cell Lung Cancer

By  

Oncology, Vol. 81, Iss. 3-4, 2011-11 ,pp. : 273-280

Karger

Access to resources Recommend Favorite

The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients

By  

Respiration, Vol. 82, Iss. 4, 2011-01 ,pp. : 341-350

Karger

Access to resources Recommend Favorite